Chronotype, sleep, and sleepiness in Parkinson's disease.

Chronotype, sleep, and sleepiness in Parkinson's disease.
复制标题

帕金森病的睡眠时间型、睡眠和嗜睡。

DOI:
10.1016/j.parkreldis.2022.10.011
复制
发表时间:
2023
影响因子:
4.1
通讯作者:
Videnovic,Aleksandar
Videnovic,Aleksandar
中科院分区:
医学2区
文献类型:
--
作者:
Murphy,Samantha;Chibnik,LoriB;Videnovic,Aleksandar

文献摘要

相似文献

我们的目的是确定PD患者队列中时间类型的分布,并评估时间类型与PD特征之间的关系,以及自我报告的睡眠和困倦指标。采用Horne-Ostberg晨醒性问卷(MEQ)对时间型进行表征。PD参与者被分类为夜猫子(ET)、两种类型都不是(NT)或早起型(MT)。困倦程度由爱普沃斯困倦量表评估。睡眠指标包括自我报告的睡眠时间和延迟。186例PD患者完成了MEQ,年龄65.5±9.8岁,病程6.17±6.7年。大多数参与者被归类为MT(63.4%)。ET组比NT组和MT组年轻(57.6±6.3 vs 67.3±10.2 vs 64.9±9.5)。平均疾病持续时间在不同时型之间没有差异。睡眠类型和嗜睡之间没有明显的关系。MT参与者明显早于NT参与者起床和睡觉。时间类型和PD药物之间没有显著差异。进一步的研究应该检查PD的严重程度和进展是否影响时间型,以及特定的时间型是否对PD人群的生活质量、症状控制和药物有效性有差异影响。
We aimed to determine the distribution of chronotypes in a cohort of PD patients and to evaluate the relationships between chronotype and PD characteristics, and self-reported metrics of sleep and sleepiness. Chronotype was characterized using the Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ). PD participants were categorized as Evening Types (ET), Neither Types (NT), or Morning Types (MT). Sleepiness was assessed by the Epworth Sleepiness Scale. Sleep metrics included self-reported sleep times and latency. 186 participants with PD, age 65.5 ± 9.8 yrs, disease duration 6.17 ± 6.7 yrs completed the MEQ. Most participants were classified as MT (63.4%). Participants in the ET group were younger than those in the NT and MT groups (57.6 ± 6.3 vs 67.3 ± 10.2 vs 64.9 ± 9.5). The mean disease duration was not different among chronotypes. No significant relationship between chronotype and sleepiness was found. MT participants woke up and went to bed significantly earlier than NT participants. There was no significant difference between chronotypes and PD medications. Further studies should examine if PD severity and progression affect the chronotype, and whether certain chronotype differentially affects the quality of life, symptom control, and medication effectiveness in the PD population.